홈MCP워크벤치Skills
홈워크벤치알림마이페이지
llms.txt · MCP 가이드개인정보처리방침 · 이용약관 · 지원v1.8.3
  1. 홈
  2. /화합물

설핀피라존

Sulfinpyrazone

HCID 5342
새 반응
인쇄
기본 정보개요이름 및 식별자물성안전 및 규제화학 및 산업관련 반응화합물 노트
부분 구조 검색유사 구조 찾기

기본 정보

CAS
57-96-5
표준 SMILES
O=C1C(CCS(=O)c2ccccc2)C(=O)N(c2ccccc2)N1c1ccccc1
InChIKey
MBGGBVCUIVRRBF-UHFFFAOYSA-N
분자식
C23H20N2O3S
평균 분자량
404.5 g/mol
단동위원소 질량
404.11946368

개요

Sulfinpyrazone is a sulfoxide and a member of pyrazolidines. It has a role as a uricosuric drug.

이름 및 식별자

우선 이름
Sulfinpyrazone
IUPAC
4-[2-(benzenesulfinyl)ethyl]-1,2-diphenylpyrazolidine-3,5-dione
현지명
설핀피라존
영어명
(+/-)-Sulfinpyrazone
분자식
C23H20N2O3S
분자량
404.48

이름 및 동의어

sulfinpyrazone57-96-5SulphinpyrazoneAnturaneAnturanDiphenylpyrazoneSulfoxyphenylpyrazolidineSulfinpyrazonAnturidinEnturenAnturanil1,2-Diphenyl-4-(2-(phenylsulfinyl)ethyl)pyrazolidine-3,5-dione
이름 더 보기
설핀피라존g28315anturenenturang28,315
AnturanoUSAF GE-13SulfinpirazonaSulfinpyrazonum4-[2-(benzenesulfinyl)ethyl]-1,2-diphenylpyrazolidine-3,5-dioneDTXSID00236184-(Phenylsulfoxyethyl)-1,2-diphenyl-3,5-pyrazolidinedione1,2-Diphenyl-4-(2'-phenylsulfinethyl)-3,5-pyrazolidinedione

데이터베이스 식별자

CAS
57-96-5
PubChem CID
5342
DTXSID
DTXSID0023618
ChEMBL
CHEMBL832
ChEBI
CHEBI:9342
UNII
V6OFU47K3W
EC Number
200-357-4
Nikkaji
J1.384F

물성

구조 계산 물성

XLogP
2.3
극성 표면적
76.9 Ų
수소 결합 공여자 수
0
수소 결합 수용자 수
4
회전 가능 결합 수
6
무거운 원자 수
29
형식 전하
0
복잡도
571

실험 및 물리화학적 성질

LogP · 2건

2.4

3.56

Color/FormWHITE TO OFF-WHITE
Solubility · 5건

SOL IN ETHYL ACETATE, CHLOROFORM

SLIGHTLY SOL IN WATER, ALC, ETHER, MINERAL OILS

SLIGHTLY SOL IN FATS

1 G SOL IN 10 ML ACETONE & 10 ML 0.5 N NAOH

For more Solubility (Complete) data for SULFINPYRAZONE (6 total), please visit the HSDB record page.

Human Drugs · 2건

FDA approved drugs -> Active ingredient

FDA approved drugs -> Active ingredient

Melting Point · 4건

136-137 °C

136-137 °C

MELTING POINT: 130-133 °C /D-FORM, L-FORM/

136 - 137 °C

Physical DescriptionSolid
Stability/Shelf LifeSTABLE TO LIGHT & AIR
Dissociation Constants · 2건

3.25

PKA: 2.8

Collision Cross Section · 2건

193.5 Ų [M+H]+ [CCS Type: TW; Method: calibrated with polyalanine and drug standards]

안전 및 규제

안전 정보는 참고용이며, 공급업체의 물질안전보건자료(SDS), 관련 법규 및 전문가 평가를 대체하지 않습니다.

GHS 분류

GHS Classification · 4건

Warning

H302 (100%): Harmful if swallowed [Warning Acute toxicity, oral]

P264, P270, P301+P317, P330, and P501 (click each P-code to see the statement)

Aggregated GHS information provided per 70 reports by companies from 1 notifications to the ECHA C&L Inventory.

유해성 정보

Other Safety InformationIMAP assessments - 3,5-Pyrazolidinedione, 1,2-diphenyl-4-[2-(phenylsulfinyl)ethyl]-: Human health tier I assessment
Hazard Classes and CategoriesAcute Tox. 4 (100%)

독성 정보

Interactions · 3건

...URICOSURIC ACTION /OF SULFINPYRAZONE/ IS ADDITIVE TO THAT OF PROBENECID & PHENYLBUTAZONE BUT IS MUTUALLY ANTAGONISTIC TO THAT OF SALICYLATES. ... POSSESSES ABILITY TO DISPLACE OTHER ORG ANIONS THAT ARE BOUND EXTENSIVELY TO PLASMA PROTEINS...THUS ALTERING THEIR DISTRIBUTION TO TISSUES & THEIR RENAL EXCRETION...

...SULFINPYRAZONE MAY POTENTIATE ACTIONS OF INSULIN & ORAL HYPOGLYCEMIC AGENTS...

SULFINPYRAZONE MAY DISPLACE SULFONAMIDES FROM PLASMA PROTEIN BINDING SITES...

Human Toxicity Excerpts · 2건

HYPERSENSITIVITY REACTIONS, USUALLY A RASH WITH FEVER, DO OCCUR.../OCCASIONALLY/

SIDE EFFECTS INCL UPPER GI DISTURBANCES...&, RARELY, ANEMIA, LEUKOPENIA, AGRANULOCYTOSIS, & THROMBOCYTOPENIA.

안전 데이터

wgk
3
rtecs
UQ8575000
HS 번호
2933194350

화학 및 산업

약리 정보

ATC Code · 2건

M - Musculo-skeletal system

QM - Musculo-skeletal system

Protein Binding98-99%
Pharmacodynamics · 1건

Sulfinpyrazone's pharmacologic activity is the potentiation of the urinary excretion of uric acid. It is useful for reducing the blood urate levels in patients with chronic tophaceous gout and acute intermittent gout, and for promoting the resorption of tophi.

Mechanism of Action · 2건

Sulfinpyrazone is an oral uricosuric agent (pyrazolone derivative) used to treat chronic or intermittent gouty arthritis. Sulfinpyrazone competitively inhibits the reabsorption of uric acid at the proximal convoluted tubule, thereby facilitating urinary excretion of uric acid and decreasing plasma urate concentrations. This is likely done through inhibition of the urate anion transporter (hURAT1) as well as the human organic anion transporter 4 (hOAT4). Sulfinpyrazone is not intended for the treatment of acute attacks because it lacks therapeutically useful analgesic and anti-inflammatory effects. Sulfinpyrazone and its sulfide metabolite possess COX inhibitory effects. Sulfinpyrazone has also been shown to be a UDP-glucuronsyltransferase inhibitor and a very potent CYP2C9 inhibitor. Sulfinpyrazone is also known to be a cystic fibrosis transmembrane conductance regulator (CFTR) inhibitor as well as an inhibitor of several multridrug resistance proteins (MRPs).

...IN SUFFICIENT DOSAGE IS POTENT INHIBITOR OF RENAL TUBULAR REABSORPTION OF URIC ACID. ...SMALL DOSES MAY REDUCE EXCRETION...PRESUMABLY BY INHIBITING SECRETORY BUT NOT REABSORPTIVE TRANSPORT. BY COMPETITIVE INHIBITION...REDUCES RENAL TUBULAR SECRETION OF OTHER ORG ANIONS...AS PAH /PARA-AMINOHIPPURIC/ & SALICYLIC ACID.

Biological Half-LifeApproximately 4-6 hours
Metabolism/Metabolites · 3건

MOST OF DRUG (90%) IN URINE IS UNCHANGED; REMAINDER IS ELIMINATED AS N1-P-HYDROXYPHENYL METABOLITE...

.../IN RAT/ 28%...IN URINE & 24%...IN FECES & BILE WAS FOUND AS P-HYDROXYSULFINPYRAZOLE.

Sulfinpyrazone has known human metabolites that include Sulfinpyrazone sulfone.

관련 반응

6건
반응 기록 만들기
HRID 156978 반응식
HRID 156978생성물로
HRID 833034 반응식
HRID 833034반응물로
HRID 1577634 반응식
HRID 1577634생성물로
HRID 1577636 반응식
HRID 1577636생성물로
HRID 1577637 반응식
HRID 1577637생성물로
HRID 1719691 반응식
HRID 1719691반응물로

화합물 노트

이 페이지에서기본 정보개요이름 및 식별자물성안전 및 규제화학 및 산업관련 반응화합물 노트

193.18 Ų [M+H]+ [CCS Type: TW; Method: calibrated with polyalanine and drug standards]

Other Experimental Properties · 3건

CRYSTALS FROM CHLOROFORM & HEPTANE; CRYSTALS FROM ETHANOL /D-FORM/; CRYSTALS /L-FORM/

SPECIFIC OPTICAL ROTATION: +67.1 DEG @ 22 °C/D (C= 2.04 IN ETHANOL); +109.3 DEG @ 25 °C/D (C= 0.5 IN CHLOROFORM) /D-/

SPECIFIC OPTICAL ROTATION: -64.2 DEG @ 23 °C/D (C= 2.14 IN ETHANOL); -104.5 DEG @ 26 °C/D (C= 0.5 IN CHLOROFORM) /L-/

물리화학적 성질

녹는점
136 · 136-137°
끓는 점
590.8 · 590.8±42.0 °C(Predicted)
밀도
1.189 · 1.1890 (rough estimate)
굴절률
1.636 · 1.6360 (estimate)
저장 조건
Sealed in dry,Room Temperature
용해도
물에는 매우 약간 용해되며, 에탄올에는 거의 용해되지 않습니다(96%). 알칼리 수산화물의 묽은 용액에 용해됩니다.
물리적 상태
Solid
산도 계수 (pKa)
2.8 · pKa 2.8(H2O t = RT I undefined) (Uncertain)
색상
황백색부터 연한 갈색까지
수용성
2.601 g/L · 2.601g/L(22 ºC)
주요 응용
청소용품화장품음식 및 음료법의학 및 독성학개인 위생 관리의약품(소분자)수의사
InChI
1S/C23H20N2O3S/c26-22-21(16-17-29(28)20-14-8-3-9-15-20)23(27)25(19-12-6-2-7-13-19)24(22)18-10-4-1-5-11-18/h1-15,21H,16-17H2
InChIKey
MBGGBVCUIVRRBF-UHFFFAOYSA-N
SMILES
O=C1C(CCS(=O)c2ccccc2)C(=O)N(N1c3ccccc3)c4ccccc4
NIST
Sulfinpyrazone(57-96-5)

화학적 성질

White or almost white powder.

risk_code
22
hazard_code
Xn
safety_code
36
Hazard Classifications
Acute Tox. 4 Oral
스토리지 클래스
11 - Combustible Solids
유해 물질 데이터
57-96-5(Hazardous Substances Data)
MeSH Pharmacological ClassificationGout suppressants that act directly on the renal tubule to increase the excretion of uric acid, thus reducing its concentrations in plasma.
Absorption, Distribution and Excretion · 5건

...WELL ABSORBED AFTER ORAL ADMIN. ...BOUND TO PLASMA PROTEINS...98-99%. T/2... IN PLASMA AFTER IV INJECTION IS ABOUT 3 HR. AFTER ORAL ADMIN...URICOSURIC EFFECT MAY PERSIST FOR...10 HR. ALTHOUGH LITTLE...IS AVAILABLE FOR FILTRATION @ GLOMERULUS, IT IS SECRETED BY PROXIMAL TUBULE & UNDERGOES LITTLE PASSIVE BACK DIFFUSION...

APPROX HALF OF ORALLY ADMIN DOSE APPEARS IN URINE WITHIN 24 HR. MOST OF DRUG (90%) IN URINE IS UNCHANGED; REMAINDER IS ELIMINATED AS...METABOLITE...

...RAPIDLY EXCRETED IN MAN, TOGETHER WITH P-HYDROXYLATED METABOLITE. PLASMA T/2...IN RATS...16.2 HR, &...18% OF IP DOSE...WAS EXCRETED INTO URINE. PLASMA T/2 IN MAN...BETWEEN 1 & 3 HR. MAIN ROUTE OF ELIMINATION IN RAT...FECES (68% OF DOSE)...CONSIDERABLE PORTION...EXCRETED IN BILE WAS REABSORBED FROM INTESTINAL TRACT.

...SULFINPYRAZONE...IS EXCRETED IN URINE OF RATS TO ONLY A SMALL EXTENT. ... CLEARED FROM CIRCULATION MAINLY THROUGH BILE...NO EVIDENCE OF ENTERO-HEPATIC CIRCULATION MECHANISM.

UNCHANGED DRUG /IN RAT/ WAS PRINCIPAL EXCRETION PRODUCT & ONLY 28%...IN URINE & 24%...IN FECES & BILE WAS FOUND AS P-HYDROXYSULFINPYRAZOLE. FAILURE OF RAT TO EXCRETE A HIGH PROPORTION OF THE DRUG IN URINE MAY BE RELATED TO ITS LACK OF URICOSURIC PROPERTIES IN THIS SPECIES.

Cellular LocationsCytoplasm

용도 및 제조

UsesMEDICATION
Methods of Manufacturing · 2건

SYNTHESIS: PFISTER, HAFLIGER, HELV CHIM ACTA 44, 232 (1961).

[2-(PHENYLSULFINYL)ETHYL]MALONIC ACID DIETHYL ESTER IS CONDENSED WITH HYDRAZOBENZENE WITH AID OF SOLN OF SODIUM ETHOXIDE IN ABSOLUTE ETHANOL. ... /ADDN/ XYLENE & HEATING @...130 DEG...ETHANOL...IS REMOVED. SULFINPYRAZONE IS ISOLATED BY SOLVENT EXTRACTION...& RECRYSTALLIZED FROM ETHANOL. US PATENT 2,700,671.

Formulations/PreparationsANTURANE (GEIGY). ORAL: CAPSULES 200 MG; TABLETS 100 MG.
응용 분야 · 3건

개요Sulfinpyrazone is soluble in alkaline solutions. Its synthesis is similar to that of phenylbutazone (Fig. 36.33). It produces its uricosuric effect in a manner similar to that of probenecid. A dose of 35 mg produces a uricosuric effect equivalent to that produced by 100 mg of probenecid, whereas 400 mg/day of sulfinpyrazone produces an effect comparable to that obtained with doses of 1.5 to 2 g of probenecid. It also possesses, not surprisingly, some of the properties of phenylbutazone. It is an inhibitor of human platelet prostaglandin synthesis at the cyclooxygenase step, resulting in a decrease in platelet release and a reduction in platelet aggregation. This antiplatelet effect suggests a role for sulfinpyrazone in reducing the incidence of sudden death, which can occur in the first year following a myocardial infarction; however, it lacks the analgetic and anti-inflammatory effects of phenylbutazone.

용도As an anti-inflammatory and uricosuric agent, its side effects were severe enough to preclude its continuous use in the treatment of chronic gout. Evaluation of several chemical congeners indicated that the phenylthioethyl analog of phenylbutazone had promising anti-inflammatory and uricosuric activity. A metabolite, the sulfoxide pyrazone, exhibited enhanced uricosuric activity. Interestingly, the corresponding sulfone does not appear to be a metabolite. Sulfinpyrazone lacks the clinically striking anti-inflammatory and analgesic properties of phenylbutazone.

일반 설명Sulfinpyrazone (Anturane) produces its uricosuric action ina similar manner to that of probenecid and is indicated forthe treatment of chronic and recurrent gouty arthritis. It iswell absorbed with approximately 50% of the administereddose excreted as unchanged drug into the renal tubules. Therest of the drug is primarily metabolized via CYP2C9 intothe corresponding sulfide and sulfone metabolites, thus itcan potentiate the anticoagulant effect of warfarin.

상·하류 제품 정보

상류 원료

나트륨과옥시모노황 산1,2-디페닐-4-(2-페닐티오에틸)피라졸리딘-3,5-디온중탄산나트륨(중조)초산에틸중아황산나트륨아세트산(빙초산)톨루엔